ArticleThoracic cancer2021

Efficacy and safety profile of combining programmed cell death-1 (PD-1) inhibitors and antiangiogenic targeting agents as subsequent therapy for advanced or metastatic non-small cell lung cancer (NSCLC).

Ziyi Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.